Presentation on theme: "Cannabis Youth Treatment (CYT) Trials: 12 and 30 Month Main Findings Michael Dennis, Ph.D. (On Behalf of the CYT Steering Committee) Chestnut Health Systems."— Presentation transcript:
Cannabis Youth Treatment (CYT) Trials: 12 and 30 Month Main Findings Michael Dennis, Ph.D. (On Behalf of the CYT Steering Committee) Chestnut Health Systems Bloomington, IL Presentation for SAMHSA Center for Substance Abuse Treatment (CSAT) Effective Adolescent Treatment (EAT) Grantee meeting, Baltimore, MD, November 3-5, September 19, 2003. The opinions are those of the author do not reflect official positions of the government. Available on-line at www.chestnut.org/li/posters. www.chestnut.org/li/posters
Acknowledgement This presentation is based on the work, input and contributions from several other people including: Nancy Angelovich, Tom Babor, Laura (Bunch) Brantley, Joseph A. Burleson, George Dent, Guy Diamond, James Fraser, Michael French, Rod Funk, Mark Godley, Susan H. Godley, Nancy Hamilton, James Herrell, David Hodgkins, Ronald Kadden, Yifrah Kaminer, Tracy L. Karvinen, Pamela Kelberg, Jodi (Johnson) Leckrone, Howard Liddle, Barbara McDougal, Kerry Anne McGeary, Robert Meyers, Suzie Panichelli-Mindel, Lora Passetti, Nancy Petry, M. Christopher Roebuck, Susan Sampl, Meleny Scudder, Christy Scott, Melissa Siekmann, Jane Smith, Zeena Tawfik, Frank Tims, Janet Titus, Jane Ungemack, Joan Unsicker, Chuck Webb, James West, Bill White, Michelle White, Caroline Hunter Williams, the other CYT staff, and the families who participated in this study. This presentation was supported by funds and data from the Center for Substance Abuse Treatment (CSAT’s) Persistent Effects of Treatment Study (PETS, Contract No. 270-97-7011) and the Cannabis Youth Treatment (CYT) Cooperative Agreement (Grant Nos. TI11317, TI11320, TI11321, TI11323, and TI11324). The opinions are those of the author and steering committee and do not reflect official positions of the government.
CYT Cannabis Youth Treatment Randomized Field Trial Sponsored by: Center for Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services Coordinating Center: Chestnut Health Systems, Bloomington, IL, and Chicago, IL University of Miami, Miami, FL University of Conn. Health Center, Farmington, CT Sites: Univ. of Conn. Health Center, Farmington, CT Operation PAR, St. Petersburg, FL Chestnut Health Systems, Madison County, IL Children’s Hosp. of Philadelphia, Phil.,PA
Marijuana Use is starting at younger ages Is at an historically high level among adolescents Potency increased 3-fold from 1980 to 1997 Is three times more likely to lead to dependence among adolescents than adults Is associated with many health, mental and behavioral problems Is the leading substance mentioned in adolescent emergency room admissions and autopsies
Treatment Marijuana related admissions to adolescent substance abuse treatment increased by 115% from 1992 to 1998 Over 80% of adolescents entering treatment in 1998 had a marijuana problem Over 80% are entering outpatient treatment Over 75% receive less than 90 days of treatment (median of 6 weeks) Evaluations of existing adolescent outpatient treatment suggest that last than 90 days of outpatient treatment is rarely effective for reducing marijuana use.
Purpose of CYT To learn more about the characteristics and needs of adolescent marijuana users presenting for outpatient treatment. To adapt evidence-based, manual-guided therapies for use in 1.5 to 3 month adolescent outpatient treatment programs in medical centers or community based settings. To field test the relative effectiveness, cost, cost- effectiveness, and benefit cost of five interventions targeted at marijuana use and associated problems in adolescents. To provide validated models of these interventions to the treatment field in order to address the pressing demands for expanded and more effective services.
Design Target Population: Adolescents with marijuana disorders who are appropriate for 1 to 3 months of outpatient treatment. Inclusion Criteria: 12 to 18 year olds with symptoms of cannabis abuse or dependence, past 90 day use, and meeting ASAM criteria for outpatient treatment Data Sources: self report, collateral reports, on-site and laboratory urine testing, therapist alliance and discharge reports, staff service logs, and cost analysis. Random Assignment: to one of three treatments within site in two research arms and quarterly follow-up interview for 12 months Long Term Follow-up: under a supplement from PETSA follow-up was extended to 30 months (42 for a subsample)
Randomly Assigns to: MET/CBT5 Motivational Enhancement Therapy/ Cognitive Behavioral Therapy (5 weeks) MET/CBT12 Motivational Enhancement Therapy/ Cognitive Behavioral Therapy (12 weeks) FSN Family Support Network Plus MET/CBT12 (12 weeks) ACRA Adolescent Community Reinforcement Approach(12 weeks) MDFT Multidimensional Family Therapy Trial 2Trial 1 Incremental ArmAlternative Arm Two Trials or Study Arms Randomly Assigns to: MET/CBT5 Motivational Enhancement Therapy/ Cognitive Behavioral Therapy (5 weeks) (12 weeks) Source: Dennis et al, 2002
Contrast of the Treatment Structures Individual Adolescent Sessions CBT Group Sessions Individual Parent Sessions Family Sessions/Home Visits Parent Education Sessions Total Formal Sessions Type of Service MET/ CBT5 MET/ CBT12 FSNACRAMDFT 2 3 5 2 10 12 2 10 4 6 22 10 2 2 14 6 3 6 15 Case management/ Other Contacts As needed Total Expected Contacts51222+14+15+ Total Expected Hours51222+14+15+ Total Expected Weeks6-712-13 Source: Diamond et al, 2002
Actual Treatment Received by Condition Source: Dennis et al, under review MET/CBT12 adds 7 more sessions of group FSN adds multi family group, family home visits and more case management ACRA and MDFT both rely on individual, family and case management instead of group With ACRA using more individual therapy And MDFT using more family therapy
$1,559 $1,413 $1,984 $3,322 $1,197 $1,126 $- $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 $4,000 MET/CBT5 (6.8 weeks) MET/CBT12 (13.4 weeks) FSN (14.2 weeks w/family) MET/CBT5 (6.5 weeks) ACRA (12.8 weeks) MDFT(13.2 weeks w/family) $1,776 $3,495 NTIES Est (6.7 weeks) NTIES Est.(13.1 weeks) Average Cost Per Client-Episode of Care |--------------------------------------------Economic Cost-------------------------------------------|-------- Director Estimate-----| Average Episode Cost ($US) of Treatment Source: French et al., 2002 Less than average for 6 weeks Less than average for 12 weeks
Implementation of Evaluation Over 85% of eligible families agreed to participate Quarterly follow-up of 94 to 98% of the adolescents from 3- to 12-months (88% all five interviews) Long term follow-up completed on 90% at 30-months and 91% (of 116 subsample) at 42-months Collateral interviews were obtained at intake, 3- and 6-months on over 92-100% of the adolescents interviewed Urine test data were obtained at intake, 3, 6, 30 and 42 months 90-100% of the adolescents who were not incarcerated or interviewed by phone (85% or more of all adolescents). Self report marijuana use largely in agreement with urine test at 30 months (13.8% false negative, kappa=.63) 5 Treatment manuals drafted, field tested, revised, send out for field review, and finalized (10-30,000 copies of each already printed and distributed) Descriptive, outcome and economic analyses completed Source: Dennis et al, 2002, under review
Adolescent Cannabis Users in CYT were as or More Severe Than Those in TEDS* Source: Tims et al, 2002
Demographic Characteristics Source: Tims et al, 2002
Institutional Involvement Source: Tims et al, 2002
Patterns of Substance Use 9% 17% 71% 73% 0% 20% 40% 60% 80% 100% Weekly Tobacco Use Weekly Cannabis Use Weekly Alcohol Use Significant Time in Controlled Environment Source: Tims et al, 2002
Multiple Problems are the NORM Self-Reported in Past Year Source: Dennis et al, under review
Co-occurring Problems are Higher for those Self-Reporting Past Year Dependence Source: Tims et al., 2002 * p<.05
CYT Increased Days Abstinent and Percent in Recovery (no use or problems while in community) Source: Dennis et al., under review
Similarity of Clinical Outcomes by Conditions Source: Dennis et al., under review
Moderate to large differences in Cost-Effectiveness by Condition Source: Dennis et al., under review MET/CBT5 and 12 did better than FSN ACRA did better than MET/CBT5, and both did better than MDFT
Evaluating the Long Term Effects of Treatment Short Term Outcome Stability Difference between average of early (3-6) and latter (9-12) follow-up interviews Treatment Outcome Difference between intake and average of all short term follow-ups (3-12) Long Term Stability Difference between average of short term follow-ups (3-12) and long term follow-up (30) Source: Dennis et al, under review, forthcoming Month Z-Score
Change in Substance Frequency Scale in CYT Trial 1: Incremental Arm Months from Intake Source: Dennis et al, forthcoming Treatment Outcome: -Use reduced (-34%) - No Sig. Dif. by condition Short Term Stability: - Outcomes stable (-1%) - No Sig. Dif. by condition Long Term Stability: - Use increases (+64%) - No Sig. Dif. by condition
Change in Number of Substance Problems in CYT Trial 1: Incremental Arm Months from Intake Source: Dennis et al, forthcoming Long Term Stability: -Problems increase (+17%) -Sig. Dif. by condition (+37% vs +10% vs +7%) Treatment Outcome: -Problems reduced (-46%) - Sig. Dif. by condition (-50% vs. –33% vs. –51%) Short Term Stability: -Further reductions (-25%) - No difference by condition
Change in Substance Frequency Scale in CYT Trial 2: Alternative Arm Months from Intake Source: Dennis et al, forthcoming Treatment Outcome: - Use reduced (-35%) - No Sig. Dif. by condition Short Term Stability: -Further reductions (-6%) - Sig. Dif. by condition (+4% vs. –10% vs. –11%) Long Term Stability: - Outcomes stable (+20%) -No Sig. Dif. by condition
Change in Number of Substance Problems in CYT Trial 2: Alternative Arm Months from Intake Source: Dennis et al, forthcoming Long Term Stability: - Outcomes stable (+7%) -No Sig. Dif. by condition Treatment Outcome: - Problems reduced (-43%) - No difference by condition Short Term Stability: - Outcomes stable (-8%) - No Sig. Dif. by condition
Percent in Past Month Recovery (no use or problems while living in the community) Source: Dennis et al, forthcoming
Cumulative Recovery Pattern at 30 months: (The Majority Vacillate in and out of Recovery) Source: Dennis et al, forthcoming
Cost Per Person in Recovery at 12 and 30 Months After Intake by CYT Condition Source: Dennis et al., under review; forthcoming $0 $5,000 $10,000 $15,000 $20,000 $25,000 $30,000 CPPR at 30 months** $6,437 $10,405 $24,725 $27,109 $8,257 $14,222 CPPR at 12 months* $3,958 $7,377 $15,116 $6,611 $4,460 $11,775 MET/ CBT5MET/ CBT12FSNMMET/ CBT5ACRAMDFT Trial 1 (n=299)Trial 2 (n=297) Cost Per Person in Recovery (CPPR) * P<.0001, Cohen’s f= 1.42 and 1.77 at 12 months ** P<.0001, Cohen’s f= 0.76 and 0.94 at 30 months Stability of MET/CBT-5 findings mixed at 30 months Integrated family therapy (MDFT) was more cost effective than adding it on top of treatment (FSN) at 30 months MET/CBT-5, -12 and ACRA more cost effective at 12 months
Reduction in Average Cost to Society in CYT Trial 1: Incremental Arm Source: French et al, 2003; forthcoming Includes the cost of CYT Treatment Further Reductions (-47%) occurred out to 30 months Reductions (-23%) in Average Cost to Society offset Treatment Costs within 12 months
Reduction in Average Cost to Society in CYT Trial 2: Alternative Arm Source: French et al, 2003; forthcoming Includes the cost of CYT Treatment Average Cost to Society goes up then down and does not offset Tx Costs within 12 months (+7%) Further Reductions occurred out to 30 months (-40%)
Average Cost to Society Varied More by Site than Condition $0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000 036912151821242730 Months from Intake UCHC, Farmington, CT (-24%, -44%) PAR, St. Petersburg, FL (-22%, -49%) CHS, Madison Co., IL (-8%, -51%) CHOP, Philadelphia, PA (+18%, -34%) Source: French et al, 2003; forthcoming
Reprise of Clinical Outcomes Co-occurring problems were the norm and varied with substance use severity. In Trial 1, FSN and MET/CBT5 were relatively more effective than MET/CBT12 in reducing substance abuse/dependence problems (treatment effect); With FSN doing better at holding its gains out to 30 months In Trial 2, ACRA and MDFT were more effective than MET/CBT5 in reducing substance abuse/dependence problems (treatment effect) and short term stability on substance use; With ACRA and MDFT doing better at holding their gains out to 30 months. These were not easily explained simply by dosage or level of family therapy and there was no evidence of iatrogenic effects of group therapy. While more effective than many earlier outpatient treatments, 2/3rds of the CYT adolescents were still having problems 12 months latter, 4/5ths were still having problems 30 months latter.
Reprise of Economic Outcomes There were considerable differences in the cost of providing each of the interventions. MET/CBT-5, -12 and ACRA were the most cost effective at 12 months, though the stability of the MET/CBT findings were mixed at 30 months. Reductions in Average Quarterly Cost to Society offset the cost of treatment within 12 months in trial 1 and with 30 months in trial 2. At 12 months the MET/CBT5 intervention clearly had the highest rate of return. By 30 months MET/CBT12, ACRA and MDFT were doing better and FSN was doing as well as MET/CBT in terms of costs to society. Results of clinical outcomes, cost-effectiveness, and benefit cost were different – suggesting the importance of multiple perspectives
Impact and Next Steps Papers published on design, validation, characteristics, matching, clinical contrast, treatment manuals, therapist reactions, 6 month outcomes, cost, benefit cost Papers with main clinical and cost-effectiveness findings at 12 months under review and 30 month findings being submitted this year. Interventions being replicated as part of over two dozen studies currently or about to go into the field 20 to 30,000 copies of each of the 5 manuals distributed to policy makers, providers, individual clinicians and training programs Source: Dennis et al, 2002, under review
Implications The CYT interventions provide replicable models of brief (1.5 to 3 month) treatments that can be used to help the field maintain quality while expanding capacity. While a good start, the CYT interventions were still not an adequate dose of treatment for the majority of adolescents. The majority of adolescents continued to vacillate in and out of recovery after discharge from CYT. More work needs to be done on providing a continuum of care, longer term engagement and on going recovery management.
Contact Information Michael L. Dennis, Ph.D., CYT Coordinating Center PI Lighthouse Institute, Chestnut Health Systems 720 West Chestnut, Bloomington, IL 61701 Phone: (309) 827-6026, Fax: (309) 829-4661 E-Mail: Mdennis@Chestnut.Org Manuals and Additional Information are Available at: CYT: www.chestnut.org/li/cyt/findings or www.chestnut.org/li/bookstore NCADI: www.health.org/govpubs PETSA: www.samhsa.gov/centers/csat/csat.html (then select PETS from program resources)